InnoCan Pharma Corporation
INNO
CNSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -26.88% | -2.63% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -26.88% | -2.63% | |||
| Cost of Revenue | -11.57% | -22.19% | |||
| Gross Profit | -28.44% | -0.06% | |||
| SG&A Expenses | -25.78% | 24.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.49% | 21.63% | |||
| Operating Income | 24.30% | -407.58% | |||
| Income Before Tax | 211.24% | -1,213.76% | |||
| Income Tax Expenses | -219.09% | 6.80% | |||
| Earnings from Continuing Operations | 212.29% | -424.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 147.46% | -7.27% | |||
| Net Income | 202.47% | -230.00% | |||
| EBIT | 24.30% | -407.58% | |||
| EBITDA | 24.61% | -398.02% | |||
| EPS Basic | 202.89% | -229.88% | |||
| Normalized Basic EPS | 169.22% | -288.35% | |||
| EPS Diluted | 202.89% | -229.88% | |||
| Normalized Diluted EPS | 169.22% | -288.35% | |||
| Average Basic Shares Outstanding | -0.41% | 0.06% | |||
| Average Diluted Shares Outstanding | -0.41% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||